Ben Thrower is a Neurology physician affiliated with Shepherd Center. OpenAlex indexes 21 publications with 1,196 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2020 Peachtree Rd NW
Atlanta, GA 303091426
Telephone
404-352-2020Registry record last updated 5 Apr 2010.
Clinical trials
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Sponsor: Acorda Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TG Therapeutics, Inc.Program year202533 payments$28,515openpaymentsdata.cms.gov ↗
- EMD Serono, Inc.Program year202530 payments
- Amgen Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
61%Gabapentinoids10%Gabapentin90%Pregabalin10%Part D≥124 patientsSSRI8.1%Trazodone Hcl31%Citalopram Hbr29%Sertraline Hcl16%Escitalopram Oxalate15%Fluoxetine Hcl9%Part D<11 patients+ 24 more classes in this area
Musculoskeletal
17.4%gamma-Aminobutyric Acid-ergic Agonist10.4%Baclofen100%Part D≥143 patientsCentral alpha-2 Adrenergic Agonist5.1%Tizanidine Hcl100%Part D≥74 patients+ 2 more classes in this area
Cancer & immunology
12.4%Other immunostimulants5.2%Copaxone67%Glatiramer Acetate21%Glatopa13%Part D<11 patientsOther immunosuppressants2.4%Dimethyl Fumarate70%Tecfidera22%Vumerity9%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial
Multiple Sclerosis and Related Disorders
2023 - Symptom burden, management and treatment goals of people with MS spasticity: Results from SEEN-MSS, a large-scale, self-reported survey
Multiple Sclerosis and Related Disorders
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”